Clinical and Pathologic Response to Neoadjuvant Chemotherapy for Breast Cancer

项目总结/摘要：乳腺癌VICC孢子（P50 CA 098131） 本申请是为了响应被标识为NOT-CA的特别利益通知（NOSI）而提交的- 23-038. Vanderbilt-Ingram癌症中心（VICC）SPORE在乳腺癌方面的总体目标是进行 合作，多学科和基于机制的转化研究，将有最高的可能 对患有乳腺癌或有患乳腺癌风险的女性和男性的影响。该项目的行政补充， NCI全球肿瘤学指导研究将评估乳腺癌新辅助化疗的反应 在肯尼亚Kijabe接受乳腺癌治疗的患者中， 在范德比尔特大学医学中心的研究人员和一名教员（一名医学博士）之间， AIC Kijabe医院的肿瘤学家/放射肿瘤学家）。克莉丝汀姆瓦基奥博士（医学/放射肿瘤学）是一名 职业生涯早期的中低收入国家研究人员（ESLI），积极参与乳腺癌的护理 肯尼亚的病人。她提出了一个两部分的研究。首先，她将评估新辅助化疗的临床反应， 化疗以及对治疗的反应与患者人口统计学、肿瘤 特征，健康和治疗方案的社会决定因素， Kijabe医院其次，她将比较乳腺癌的分子亚型与新辅助化疗的反应， 化疗，与肯尼亚Kijabe的残留癌症负荷评分相关。这笔资金将用于 支持ESLI的工资，两个研究助理，笔记本电脑的研究助理完成这一点 项目，资金进行免疫组织化学分析，对乳腺活检标本和手术乳腺 标本，并使用公共交通工具，让研究中的患者返回肯尼亚Kijabe进行随访。博士 Ben Park（内科肿瘤学）和Rondi Kauffmann博士（乳腺外科肿瘤学）组成了这项研究 范德比尔特大学的导师团队作为主要导师，考夫曼博士将负责职业发展， ESLI的研究项目指导。在这个角色中，她将通过zoom每周与她会面，将前往 肯尼亚Kijabe进行培训，并将在范德比尔特举办一次ESLI培训。

PROJECT SUMMARY/ABSTRACT: VICC SPORE IN BREAST CANCER (P50CA098131) This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 23-038. The overall goal of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Breast Cancer is to conduct collaborative, multidisciplinary and mechanism-based translational research that will have the highest possible impact for women and men with or at risk for breast cancer. This project for the Administrative Supplement for NCI Global Oncology Mentored Research will assess response to neoadjuvant chemotherapy for breast cancer in patients undergoing breast cancer treatment in Kijabe, Kenya through a formal mentored research relationship between researchers at Vanderbilt University Medical Center and a faculty member (a medical oncologist/radiation oncologist) at AIC Kijabe Hospital. Dr. Christine Mwakio (medical/radiation oncology) is an early-career low-middle income country researcher (ESLI) who is actively involved in the care of breast cancer patients in Kenya. She proposes a two-part study. First, she will evaluate the clinical response to neoadjuvant chemotherapy and the relationship between response to therapy and patient demographics, tumor characteristics, social determinants of health and treatment regimen in patients diagnosed with breast cancer at Kijabe Hospital. Second, she will compare the molecular subtypes of breast cancer with response to neoadjuvant chemotherapy, correlating with residual cancer burden score in Kijabe, Kenya. Funds from this subcontract will support the salary of the ESLI, two research assistants, laptops for the research assistants to complete this project, funds to perform immunohistochemistry analysis on both breast biopsy specimens and surgical breast specimens, and use of public transportation for patients in the study to return to Kijabe, Kenya for follow-up. Dr. Ben Park (medical oncology) and Dr. Rondi Kauffmann (breast surgical oncology) comprise the research mentoring team at Vanderbilt. As primary mentor, Dr. Kauffmann will be responsible for career development and research project mentoring for the ESLI. In that role, she will meet with her weekly via zoom, will travel once to Kijabe, Kenya for training during the year, and will host the ESLI for training at Vanderbilt once during the year.